What evidence do we need for biomarker qualification?

Leptak, Chris; Menetski, Joseph P; Wagner, John A; Aubrecht, Jiri; Brady, Linda; Brumfield, Martha; Chin, William W; Hoffmann, Steve; Kelloff, Gary; Lavezzari, Gabriela; Ranganathan, Rajesh; Sauer, John-Michael; Sistare, Frank D; Zabka, Tanja; Wholley, David

Leptak, Chris; Menetski, Joseph P; Wagner, John A; Aubrecht, Jiri; Brady, Linda; Brumfield, Martha; Chin, William W; Hoffmann, Steve; Kelloff, Gary; Lavezzari, Gabriela; Ranganathan, Rajesh; Sauer, John-Michael; Sistare, Frank D; Zabka, Tanja; Wholley, David.

Afiliación

Leptak C; Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA.
Menetski JP; Foundation for the National Institutes of Health (NIH), North Bethesda, MD 20852, USA.
Wagner JA; Takeda Pharmaceuticals International Co., Cambridge, MA 02139, USA.
Aubrecht J; Pfizer Inc., Groton, CT 06340, USA.
Brady L; National Institute of Mental Health, NIH, Bethesda, MD 20892, USA.
Brumfield M; Critical Path Institute, Tucson, AZ 85718, USA.
Chin WW; Pharmaceutical Research and Manufacturers of America, Washington, DC 20004, USA.
Hoffmann S; Foundation for the National Institutes of Health (NIH), North Bethesda, MD 20852, USA.
Kelloff G; National Cancer Institute, NIH, Rockville, MD 20850, USA.
Lavezzari G; Biocerna LLC, Maple Lawn, MD 20759, USA.
Ranganathan R; Massachusetts General Hospital, Boston, MA 02114, USA.
Sauer JM; Critical Path Institute, Tucson, AZ 85718, USA.
Sistare FD; Merck and Co. Inc., West Point, PA 19486, USA.
Zabka T; Genentech Inc., South San Francisco, CA 94080, USA.
Wholley D; Foundation for the National Institutes of Health (NIH), North Bethesda, MD 20852, USA. dwholley@fnih.org.

Sci Transl Med ; 9(417)2017 Nov 22.

Article en En | MEDLINE | ID: mdl-29167393

RESUMEN

Biomarkers can facilitate all aspects of the drug development process. However, biomarker qualification-the use of a biomarker that is accepted by the U.S. Food and Drug Administration-needs a clear, predictable process. We describe a multistakeholder effort including government, industry, and academia that proposes a framework for defining the amount of evidence needed for biomarker qualification. This framework is intended for broad applications across multiple biomarker categories and uses.

Asunto(s)

Biomarcadores; Animales; Humanos; Estados Unidos; United States Food and Drug Administration

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Biomarcadores Tipo de estudio: Prognostic_studies Límite: Animals / Humans País/Región como asunto: America do norte Idioma: En Revista: Sci Transl Med Asunto de la revista: CIENCIA / MEDICINA Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google